Key Segments:
By Device Type
-
Self-Monitoring Blood Glucose Devices
-
Continuous Glucose Monitoring Systems
By Product
-
Glucose Meters
-
Test Strips
-
Lancets
-
CGM Sensors
-
Transmitters & Receivers
By Modality
-
Wearable
-
Non-Wearable
By Distribution Channel
-
Retail Pharmacies
-
Online Channels
-
Hospital Pharmacies
By End User
-
Home Settings
-
Hospitals and Clinics
-
Diagnostic Centers
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd., Dexcom, Inc., and Ascensia Diabetes Care Holdings AG, among other diabetes technology manufacturers.
Continued expansion of over-the-counter continuous glucose monitoring and continued integration of glucose data with AI-powered coaching platforms represent the primary opportunities.
Growth is primarily driven by the escalating global prevalence of type 1 and type 2 diabetes, combined with continued technological innovation in continuous glucose monitoring.
By Device Type, Self-Monitoring Blood Glucose Devices dominated the market in 2025, reflecting decades of established clinical use and lower per-unit cost.
North America dominated the market with a 36.85% share in 2025, supported by a substantial diabetic population and broad insurance reimbursement coverage.